Everything below concerns neurotrophic factor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
=== Rice and seafood === It's estimated that an average adult in the United States consumes 3.2 μg/day of arsenic, with a range of 1–20 μg/day. Estimates for children were similar. Food also contains many organic arsenic compounds. A wide range of arsenic containing compounds have been found in food,although arsenic compounds may range significantly in toxicity. Seafood is a common source of organic arsenic in the form of arsenobetaine. There is evidence indicating that arsenocholine, which can be found in some food sources, is non-toxic. Arsenosugars are present in some forms of seafood and been shown through in vitro studies to be significantly less toxic than both inorganic arsenic and trivalent methylated arsenic metabolites. It has been found that rice is particularly susceptible to the accumulation of arsenic from soil. Rice grown in the United States has an average 260 ppb of arsenic, but U.S. arsenic intake remains far below World Health Organization-recommended limits. China has set a standard for arsenic limits in food (150 ppb), as levels in rice exceed those in water.
==== Canada ==== Semaglutide's pharmaceutical data exclusivity period expired in Canada in January 2026. Novo Nordisk failed to pay a required patent maintenance fee, and their patent on the chemical structure of the drug expired in 2020. Several applications and approvals for generic semaglutide followed, both for type 2 diabetes and weight loss. In April 2026, Dr. Reddy's Laboratories received approval to sell generic semaglutide in injectable format in Canada, having applied in February 2024. Later that week, Apotex's generic semaglutide (Apo-Semaglutide) was also approved as an injectable drug. In June 2026, Health Canada approved Sevmia, Apotex's injectable generic semaglutide for weight management in people aged 12 years and above. In July 2026, Aspen Pharmacare received approval for a generic injectable form of the drug for diabetes (Aspen-Semaglutide). Several other applications to sell generic versions have been made, but not yet approved, including by Sandoz, Taro Pharmaceuticals and Teva Pharmaceuticals. Hims & Hers Health expects to partner with an approved manufacturer to market a generic version. Sandoz' 2026 offering would be for diabetes only, while Biocon hopes to offer generic semaglutide for diabetes and weight loss by 2027. Novo Nordisk is considering competing against the new generic drugs with Plosbrio and Poviztra: additional brand names for semaglutide, but marketed at a lower price than Ozempic and Wegovy.
As described by Jeong et al., compared with other do novo peptide sequencing tools, which works well on only certain types of spectra, UniNovo is a more universal tool that has a good performance on various types of spectra or spectral pairs like CID, ETD, HCD, CID/ETD, etc. It has a better accuracy than PepNovo+ or PEAKS. Moreover, it generates the error rate of the reported peptide sequences. Ma published Novor in 2015 as a real-time de novo peptide sequencing engine. The tool is sought to improve the de novo speed by an order of magnitude and retain similar accuracy as other de novo tools in the market. On a Macbook Pro laptop, Novor has achieved more than 300 MS/MS spectra per second. Pevtsov et al. compared the performance of the above five de novo sequencing algorithms: AUDENS, Lutefisk, NovoHMM, PepNovo, and PEAKS . QSTAR and LCQ mass spectrometer data were employed in the analysis, and evaluated by relative sequence distance (RSD) value, which was the similarity between de novo peptide sequencing and true peptide sequence calculated by a dynamic programming method. Results showed that all algorithms had better performance in QSTAR data than on LCQ data, while PEAKS as the best had a success rate of 49.7% in QSTAR data, and NovoHMM as the best had a success rate of 18.3% in LCQ data. The performance order in QSTAR data was PEAKS > Lutefisk, PepNovo > AUDENS, NovoHMM, and in LCQ data was NovoHMM > PepNovo, PEAKS > Lutefisk > AUDENS. Compared in a range of spectrum quality, PEAKS and NovoHMM also showed the best performance in both data among all 5 algorithms.
The island chain strategy is a strategic maritime containment plan first conceived by American foreign policy statesman John Foster Dulles in 1951, during the Korean War. It proposed surrounding the Soviet Union and China with naval bases in the West Pacific to project power and restrict sea access. The "island chain" concept did not become a major theme in American foreign policy during the Cold War, but after the dissolution of the Soviet Union it has remained a significant focus of both American and Chinese geopolitical and military analysts. For the United States, the island chain strategy is a significant part of the force projection of the U.S. military in the Far East. For the People's Republic of China (PRC), the concept is integral to its maritime security and fears of strategic encirclement by the U.S. and its allies. For both the U.S. and the PRC, the island chain strategy emphasizes the geographical and strategic importance of Taiwan.
Sources: en.wikipedia.org
=== House of Representatives === In 1968, Mizell was elected to represent the 5th District in the 91st United States Congress. He defeated Democratic nominee Smith Bagley, an R.J. Reynolds Tobacco Company official, 84,905 (52.4 percent) to 77,112 (47.6 percent). The previous 5th District representative, Democrat Nick Galifianakis, was moved to the 4th District for the 1968 elections. A supporter of Richard Nixon, Mizell ran on a platform vehemently opposed to federal spending and Communism. In his first term, he spoke in favor of trade legislation. "I believe no nation in the world need fear the Trade Bill of 1970," he said, praising it for its benefits to foreign nations and American workers alike.
He played Sigmund Freud's father in Freud: The Secret Passion (1962) with Montgomery Clift in the lead. He was also well known for his story-telling skills, particularly in reinterpreting the Bible. His best-known book, also a television series, is The Book of Witnesses (1971), in which he turned the Gospels into a series of monologues. He also retold dozens of Old Testament and Apocrypha stories in Bible Stories (1968).
Not all cnidarians reproduce sexually, but many species have complex life cycles of asexual polyp stages and sexual medusae stages. Some, however, omit either the polyp or the medusa stage, and the parasitic classes evolved to have neither form. Cnidarians were formerly grouped with ctenophores, also known as comb jellies, in the phylum Coelenterata, but increasing awareness of their differences caused them to be placed in separate phyla. Most cnidarians are classified into four main groups: the almost wholly sessile Anthozoa (sea anemones, corals, sea pens); swimming Scyphozoa (jellyfish); Cubozoa (box jellies); and Hydrozoa (a diverse group that includes all the freshwater cnidarians as well as many marine forms, and which has both sessile members, such as Hydra, and colonial swimmers (such as the Portuguese man o' war). Staurozoa have recently been recognised as a class in their own right rather than a sub-group of Scyphozoa, and the highly derived parasitic Myxozoa and Polypodiozoa were firmly recognized as cnidarians only in 2007. Most cnidarians prey on organisms ranging in size from plankton to animals several times larger than themselves, but many obtain much of their nutrition from symbiotic dinoflagellates, and a few are parasites. Many are preyed on by other animals including starfish, sea slugs, fish, turtles, and even other cnidarians. Many scleractinian corals—which form the structural foundation for coral reefs—possess polyps that are filled with symbiotic photo-synthetic zooxanthellae.
=== Pharmacokinetics === OHPH shows a pronounced depot effect when administered by subcutaneous injection in animals, similarly to the closely related medication hydroxyprogesterone caproate. The oral activity of OHPH in animals does not appear to have been assessed.
Following TNF-R1 and Fas activation in mammalian cells a balance between proapoptotic (BAX, BID, BAK, or BAD) and anti-apoptotic (Bcl-Xl and Bcl-2) members of the Bcl-2 family are established. This balance is the proportion of proapoptotic homodimers that form in the outer-membrane of the mitochondrion. The proapoptotic homodimers are required to make the mitochondrial membrane permeable for the release of caspase activators such as cytochrome c and SMAC. Control of proapoptotic proteins under normal cell conditions of nonapoptotic cells is incompletely understood, but in general, Bax or Bak are activated by the activation of BH3-only proteins, part of the Bcl-2 family.
Sources: en.wikipedia.org
Several phase 1 clinical trials have been performed by experts in the field of adoptive immunotherapy of cancer. Hans Klingemann and Sally Arai completed a US trial at Rush University Medical Center (Chicago) in renal cell cancer and melanoma patients in 2008, and Torsten Tonn, MD and Oliver Ottmann, MD completed the European trial at the University of Frankfurt in patients with various solid and hematological malignancies in 2013. Armand Keating at Princess Margaret Hospital in Toronto conducted a trial in which NK-92 cells were given to patients who had relapsed after autologous bone marrow transplants for leukemia or lymphoma. In all clinical trials so far, NK-92 cells were administered as a simple intravenous infusion, dosed two or three times per treatment course, and given in the outpatient setting. Of the 39 patients enrolled across the three studies, 2 serious (grade 3–4) side-effects occurred during or after the infusion of NK-92 cells, the side effects disappeared afterward. The doses given to patients ranged from 1 × 108 cells/m2 to 1 × 1010 cells/m2 per infusion. Patients received between two and three infusions over a period of less than a week. About one-third of the treated patients had clinically meaningful responses with some of them fully recovering.
Interpretation for secondary adrenal insufficiency ACTH will be low – usually below 35, but most people with secondary fall within the range limit. This is inappropriately normal for the low cortisol level. In some cases, the actual cause of low ACTH is from low CRH in the hypothalamus. It is possible to have separate ACTH and CRH impairment such as can happen in a head injury. The ACTH stimulation test is occasionally used to test adrenal production of aldosterone at the same time as cortisol to also help in determining if primary (hyperreninemic) or secondary (hyporeninemic) hypoaldosteronism is present. Human ACTH has a slight stimulatory effect on aldosterone, but the amount of synthetic ACTH given in the stimulation is equivalent to more than a whole days production of natural ACTH, so the aldosterone response can be easily measured in blood serum. Same as cortisol, aldosterone should double from a respectable base value (around 20 ng/dl, must fast salt 24 hours and sit upright for blood draw) in a healthy individual.
Americium-242 has a half-life of only 16 hours, which makes its further conversion to 243Am extremely inefficient. The latter isotope is produced instead in a process where 239Pu captures four neutrons under high neutron flux:
Pramlintide (trade name Symlin) is an injectable amylin analogue drug for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca). Pramlintide is sold as an acetate salt.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.